Antigenicity and Immunogenicity of Differentially Glycosylated HCV E2 Envelope Proteins Expressed in Mammalian and Insect Cells.

Title: Antigenicity and Immunogenicity of Differentially Glycosylated HCV E2 Envelope Proteins Expressed in Mammalian and Insect Cells.

Publication Type: Journal Article

Year of Publication: 2019


Journal: J Virol

Date Published: 2019 Jan 16

ISSN: 1098-5514

Abstract: Development of a prophylactic vaccine for hepatitis C virus (HCV) remains a global health challenge. Cumulative evidence indicates that antibodies against the E2 protein of HCV have protective efficacy against recurrent infection. Thus, E2 vaccine candidates have focused on inducing neutralizing antibodies. However, E2-specific antibodies are highly heterogeneous, with greater than 40% of HCV patients failing to mount a significant response to E2,

DOI: 10.1128/JVI.01403-18


PubMed ID: 30651366